Literature DB >> 15585979

Breast cancer in a male patient after treatment of acute lymphoblastic leukemia including total body irradiation and bone marrow transplantation.

D Latz1, M Alfrink, N Nassar, C Beyerle.   

Abstract

BACKGROUND: With increasing numbers of patients subjected to total body irradiation and bone marrow transplantation for treatment of several systemic malignancies more and more patients with second malignancies were observed. CASE REPORT: We report the case of a 29- year-old man who developed breast cancer 13 years after treatment for acute lymphoblastic leukemia. Therapy for leukemia included total body irradiation (TBI) and bone marrow transplantation (BMT). Breast cancer was treated with mastectomy and irradiation of the left chest wall. 17 months later the patient developed malignant pleural effusion and died despite chemotherapy and hormonal therapy due to further tumor progression.
CONCLUSION: The increased risk for secondary solid cancers after TBI and BMT and the greater risk among younger patients indicate the need for lifelong careful follow up. Copyright 2004 S. Karger GmbH, Freiburg.

Entities:  

Mesh:

Year:  2004        PMID: 15585979     DOI: 10.1159/000080369

Source DB:  PubMed          Journal:  Onkologie        ISSN: 0378-584X


  3 in total

1.  A rare complication resulting in a rare disease: radiation-induced male breast cancer.

Authors:  Jamila Alazhri; Constantine Saclarides; Eli Avisar
Journal:  BMJ Case Rep       Date:  2016-04-15

2.  Genotyping of BRCA1, BRCA2, p53, CDKN2A, MLH1 and MSH2 genes in a male patient with secondary breast cancer.

Authors:  Ana Lina Vodusek; Srdjan Novakovic; Vida Stegel; Berta Jereb
Journal:  Radiol Oncol       Date:  2011-09-22       Impact factor: 2.991

3.  Radiation associated tumors following therapeutic cranial radiation.

Authors:  Abhineet Chowdhary; Alex M Spence; Lindsay Sales; Robert C Rostomily; Jason K Rockhill; Daniel L Silbergeld
Journal:  Surg Neurol Int       Date:  2012-05-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.